On February 6, Nanhua Bio-Medicineco.Ltd(000504) (000504) received the attention letter issued by Shenzhen Stock Exchange.
On January 29, Nanhua Bio-Medicineco.Ltd(000504) disclosed the performance forecast for 2021. It is estimated that the net profit attributable to the shareholders of the listed company (hereinafter referred to as "net profit") in 2021 will be a loss of 13.5 million yuan to 16.5 million yuan, and the net profit after deduction will be a loss of 21.5 million yuan to 24.5 million yuan. The company achieved operating income of 103 million yuan in the first three quarters of 2021, and the net assets attributable to shareholders of listed companies (hereinafter referred to as "net assets") at the end of 2020 was 26.5685 million yuan.
Nanhua Bio-Medicineco.Ltd(000504) it is necessary to supplement and disclose the prediction range (or exact number) of operating revenue and operating revenue after deduction in 2021, and explain the recognition and recognition basis of operating revenue in each quarter by business, as well as the specific composition of operating revenue deductions; According to the specific deduction items listed in "4.2 matters related to deduction of operating income" in the "guidelines for self regulation and supervision of listed companies No. 1 - business handling" of Shenzhen Stock Exchange, explain in detail whether the company has completely deducted the business income irrelevant to the main business and the income without commercial substance, and whether it has pre communicated with the annual audit accountant on the deduction of operating income; Explain in detail whether the operating income of the company after deduction in 2021 is expected to be less than 100 million yuan, whether the net assets at the end of 2021 are expected to be negative, and whether it is possible to touch the situation that the delisting risk warning of stock trading specified in the stock listing rules (Revised in 2022) of Shenzhen Stock Exchange may be implemented after the disclosure of the 2021 annual report.
